Ausgabe 5/2023
Inhalt (14 Artikel)
Pharmacological assessment of the antineoplastic and immunomodulatory properties of a new spiroindolone derivative (7’,8’-Dimethoxy-1’,3’-dimethyl-1,2,3’,4’-tetrahydrospiro[indole-3,5’-pyrazolo[3,4-c]isoquinolin]-2-one) in chronic myeloid leukemia
Carlos Eduardo de Castro Alves, Serge L. Bogza, Nathalie Bohdan, Alexander B. Rozhenko, Alice de Freitas Gomes, Regiane Costa de Oliveira, Renata Galvão de Azevedo, Larissa Raquel Silva Maciel, Anamika Dhyani, Andriy Grafov, Gemilson Soares Pontes
Development of novel palbociclib-based CDK4/6 inhibitors exploring the back pocket behind the gatekeeper
Lina Li, Fengquan Chen, Mengzhe Li, Yongxiang Liao, Yongjie Wang, Wen Jiang, Yun Luan, Xia Xue
Development and characterization of fused human arginase I for cancer therapy
Snehal Sainath Jawalekar, Priyanka Sugriv Kawathe, Nisha Sharma, J Anakha, Kulbhushan Tikoo, Abhay H. Pande
Enhanced antitumor and anti-metastasis by VEGFR2-targeted doxorubicin immunoliposome synergy with NK cell activation
Mingzhu Pan, Yali Liu, Tian Sang, Jiajun Xie, Huishu Lin, Jianpeng Wei, Shuai Shao, Yanying Zheng, Juan Zhang
Lurbinectedin in patients with pretreated endometrial cancer: results from a phase 2 basket clinical trial and exploratory translational study
Rebecca Kristeleit, Alexandra Leary, Jean Pierre Delord, Victor Moreno, Ana Oaknin, Daniel Castellano, Geoffrey I. Shappiro, Cristian Fernández, Carmen Kahatt, Vicente Alfaro, Mariano Siguero, Daniel Rueda, Ali Zeaiter, Ahmad Awada, Ana Santaballa, Khalil Zaman, Jalid Sehouli, Vivek Subbiah
Cytotoxicity of poly-guanidine in medulloblastoma cell lines
Gabriel Gallo-Oller, Teresita Díaz de Ståhl, Ayodele Alaiya, Sten Nilsson, Anders R. Holmberg, Marcela Márquez-Méndez
Preclinical evaluation of the VEGF/Ang2 bispecific nanobody BI 836880 in nasopharyngeal carcinoma models
Rachel C.T. Lam, Connie W.C. Hui, C. H. Wong, K. W. Lo, Anna C.M. Tsang, Edwin P. Hui, Anthony T.C. Chan, Brigette B.Y. Ma
Clinical characteristics of liver injury induced by immune checkpoint inhibitors in patients with advanced biliary tract carcinoma
Zhao Gao, Shikai Wu, Yinmo Yang, Mingxia Sun, Xiaodong Tian, Xuan Jin
Early on-treatment C-reactive protein and its kinetics predict survival and response in recurrent and/or metastatic head and neck cancer patients receiving first-line pembrolizumab
Markus Haas, Alexander Lein, Thorsten Fuereder, Julia Schnoell, Faris F. Brkic, David T. Liu, Lorenz Kadletz-Wanke, Gregor Heiduschka, Bernhard J. Jank
A novel bivalent anti-c-MET/PD-1 bispecific antibody exhibits potent cytotoxicity against c-MET/PD-L1-positive colorectal cancer
Z. Sun, C. Gu, X. Wang, A. Shang, W. Quan, J. Wu, P. Ji, Y. Yao, W. Liu, D. Li
A novel anticancer quinolone, (R)-WAC-224, has anti-leukemia activities against acute myeloid leukemia
Tatsuji Mino, Hiroshi Ureshino, Taichi Ueshima, Naoki Kashimoto, Tomonori Yamaguchi, Kazuhito Naka, Toshiya Inaba, Tatsuo Ichinohe
Safety and blood levels of daratumumab after switching from intravenous to subcutaneous administration in patients with multiple myeloma
Kenta Yamaoka, Kei Irie, Nobuhiro Hiramoto, Masaki Hirabatake, Hiroaki Ikesue, Tohru Hashida, Tadashi Shimizu, Takayuki Ishikawa, Nobuyuki Muroi
The efficacy and safety of selective RET inhibitors in RET fusion-positive non-small cell lung cancer: a meta-analysis
Jun-yi Ke, Shu Huang, Zhi-tao Jing, Min-chao Duan